RxDoctor Payments Data

Edward Franko, MD

Colon & Rectal Surgery · Dallas, TXNPI 1316026412

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Intuitive Surgical at 40.0% of the total. Reporting peaked in 2020 at $5,544 and has fallen 87.9% since, to $670 in 2025.

$13,124in general payments, 2019–2025

Across 342 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Medtronic$1K
  • Davol Inc.$558
  • THD America, Inc.$444
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$8006%
  • Speaking & faculty fees$5004%
  • Travel & lodging$1,1449%
  • Food & beverage$6,65951%
  • Education$4,00030%
  • Gifts$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,124 in reported general payments places this provider in the 75th percentile of 200 colon & rectal surgery providers in Texas.

See all colon & rectal surgery providers in Texas

Medicare billing

Part B allowed, 2024
$193,745
Medicare patients
282
Services billed
1,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine42$15,961
LinzessLinaclotide19$12,477
TrulancePlecanatide13$7,086
Mesalamine ErMesalamine16$3,128
Hydrocortisone42$1,276
Lactated RingersRinger's Solution,lactated52$478
Procto-Med HcHydrocortisone24$439
Lidocaine18$424
Imiquimod11$245
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$235
Gabapentin12$196
Metronidazole11$94
Ciprofloxacin Hcl11$82
Tramadol Hcl19$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,826$12,47719 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$131$7,08613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 200 colon & rectal surgery providers in Texas.

Other colon & rectal surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →